Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Generalized myasthenia gravis, all serotypes (Vyvgart Hytrulo) — argenx(Approved)
Additional Janssen and BMS commercial products (product names not specified in excerpts)(Approved)
Status note Proprietary enzyme rHuPH20-based drug delivery technology that breaks down hyaluronan to enable rapid subcutaneous delivery of high-dose, high-volume injectable biologics. Ten commercial partner products earn royalties. In May 2026 argenx announced FDA approval of an sBLA expanding Vyvgart Hytrulo to all adult gMG serotypes. Partners may terminate target-by-target on 90 days' notice.
Phase 2 · ActiveModality: drug delivery technology (ENHANZE co-formulation)
Target EGFR / MET (bispecific antibody)
Partnerships Developed by Janssen Biotech under the ENHANZE collaboration and license agreement (Dec 2014; up to five targets).
Indications
Advanced head and neck squamous cell carcinoma (previously treated with immunotherapy and chemotherapy)(Phase 2)
Catalysts
— 2026 (regulatory filing submitted May 2026)
Status note Janssen's Phase 1b/2 OrigAMI-4 study of subcutaneous amivantamab with hyaluronidase-lpuj delivered durable responses in advanced HNSCC previously treated with immunotherapy and chemotherapy; supplemental BLA submitted to FDA May 2026.
TAK-881
Phase 2 · ActiveModality: drug delivery technology (ENHANZE co-formulation)
Partnerships Developed by Takeda under the ENHANZE collaboration and license agreement (2007; worldwide exclusive).
Indications
Primary immunodeficiency disease(Phase 2)
Status note Immune globulin SC (human), 20% solution with ENHANZE for primary immunodeficiency disease. Pivotal Phase 2/3 trial initiated Oct 2023; positive topline results announced by Takeda May 2026.
Adimanebart (SC formulation)
Phase 1 · ActiveModality: drug delivery technology (ENHANZE co-formulation)
Aliases ARGX-119
Partnerships Developed by argenx BVBA under the ENHANZE collaboration.
Indications
not disclosed(Phase 1)
Status note In Q3 2026 the adimanebart program was expanded to include a Phase 1 SC bioavailability study with ENHANZE.
INCA033989 (SC formulation)
Stage not disclosed · ActiveModality: drug delivery technology (ENHANZE co-formulation)
Aliases INCA033989
Target mutant calreticulin
Partnerships Incyte Corporation global collaboration and license agreement (Jul 2026) to evaluate additional SC formulations of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody, with ENHANZE; Incyte may nominate up to two additional targets.
Indications
Mutant calreticulin-expressing myeloproliferative neoplasms(Stage not disclosed)
Status note SC formulation evaluation under a new Jul 2026 ENHANZE collaboration with Incyte; upfront payment plus future milestones and royalties.
Hypercon / Surf Bio hyperconcentration technology
Preclinical · ActiveModality: drug delivery technology (microparticle hyperconcentration)
Aliases Hypercon technology
Partnerships Halozyme develops Hypercon with collaboration partners (partner funds all development, manufacturing, clinical, regulatory and commercial costs); Surf Bio drug delivery technology acquired in 2025 ($284.9M IPR&D asset; $100M contingent consideration).
Status note Microparticle technologies demonstrated in non-clinical testing to enable hyperconcentration of drugs and biologics (up to 500 mg/mL), reducing injection volume for potential single auto-injector delivery at home or in office.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.